Estrogen Replacement Therapy has been widely used in menopausal women to prevent osteoporosis and coronary heart disease. Estrogen replacement therapy has the following benefits. First, estrogen replacement therapy can significantly relieve the symptoms of the menopausal syndrome, such as facial hot flashes and night sweats. Secondly, estrogen replacement therapy is still the most effective treatment for vaginal and vulvar atrophy in menopausal women. It can improve the pain associated with sexual intercourse, one of the most common causes of sexual apathy in menopausal women. Topical application can achieve curative effects. It has also been found that topical applications can reduce the recurrence rate of urinary tract infections. There is clear evidence of estrogen replacement Therapy can prevent osteoporosis and fractures.
However, due to other more effective treatments for osteoporosis, such as Bisphosphonates, estrogen replacement therapy is no longer a first-line drug for preventing osteoporosis. In addition, estrogen replacement therapy also may reduce the incidence of colorectal cancer.
Global Estrogen Replacement Therapy Market likely to grow with a noteworthy rate during the forecast period, 2020-2027. The surge in the population of post-menopausal women across the world will accelerate the growth of the global estrogen replacement therapy market in the upcoming periods. Additionally, growing awareness of post-menopausal issues among women, coupled with the growth in drug development for menopausal issues, will fuel the global estrogen replacement therapy market in the next few years. Moreover, the rise in the geriatric population across the world and the various kinds of hormonal changes in the female body predominantly gets affected by the natural process of aging will influence the global estrogen replacement therapy industry in estimated periods.
Menopausal women can ease the function of estrogen secretion such as hot flashes, sweating, dizziness, insomnia, irritability, nameless, vaginal dryness, loss of libido, etc. with autonomic disorders based. Furthermore, the swelling awareness about menopausal symptoms among women and the growing treatment opportunities would be projected to fuel the global estrogen replacement therapy market in the future periods. In addition, augmentation in demand to prevent osteoporosis, a consequence of lowered estrogen levels, will surge the global estrogen replacement therapy market in the expected periods.
The average age of menopause in normal women is 51 years, and 95% of menopause occurs between 45 and 55 years. Menopause is associated with a significant reduction in ovarian estrogen production. Low post-menopausal estrogen levels may induce vasomotor symptoms (hot flashes), and eventually vulvar vaginal atrophy symptoms, including vaginal dryness and pain during intercourse, namely menopausal genitourinary syndrome (menopause). Estrogen is most effective in alleviating menopausal symptoms, mainly hot flashes, vaginal dryness, and pain during intercourse. Estrogen prevents thinning of the bones (osteoporosis) in menopausal women.
Based on dosages form, the global Estrogen Replacement Therapy market classified into Patches, Tablets, Gels/Creams, Suppositories, Implants, and Injections. The Tablets segment predicted to lead the market by 2027, owing to the growing demand tablet ERT for safety concerns and effective long-term therapy. They can reduce or resolve troublesome symptoms of menopause and lower the risk of osteoporosis.
The gels/creams segment will drive attributable to estrogen creams absorbed through the skin and go directly into the bloodstream, and they are safer than oral estrogen.
Based on routes of administration, the global Estrogen Replacement Therapy market categorized into Oral, Topical, Subcutaneous Pellets, Injection, and Others. The Oral segment projected to dominate the market as oral is the most preferred option for the patients. It has more favorable effects on lipid profiles, increases sex hormone-binding globulin (SHBG), and increases cortisol-binding globulin. The Topical segment will influence as it is used to treat vaginal dryness, itching, and burning in women who are experiencing menopause.
Based on end-user, the global estrogen replacement therapy market classified into Hospitals, Clinics, Pharmacy stores, and Others. Hospitals segment projected to register a higher CAGR by 2027, on account of the surge in the number of women across the globe coupled with the rise in the number of menopausal affected women worldwide.
The clinics’ segment provides immediate medicines, and consultation, along with the clinics, helps in the early detection of diseases.
Based on geography, the global Estrogen Replacement Therapy market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America estimated to occupy the lion’s market share by 2027, owing to the rising geriatric population, high awareness levels, and the surge in purchasing power of the people coupled with technological innovations in healthcare systems in these regions.
The Asia Pacific will drive increasing awareness levels and the rising focus of governments towards the eradication of hormonal deficiencies.
Companies such as AbbVie, Inc., Bayer AG, Hisamitsu Pharmaceutical Co., Inc., Novartis AG, Novo Nordisk A/S, Orion Pharma AB, Pfizer, Inc., Meda Pharmaceuticals, Teva Pharmaceutical Industries Ltd. and TherapeuticsMD, Inc. are the key players in the Global Estrogen Replacement Therapy Market.
By Dosage Forms
By Routes of Administration